Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Earns “Buy” Rating from HC Wainwright

Armata Pharmaceuticals (NYSEAMERICAN:ARMP)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $7.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 258.97% from the company’s current price.

Armata Pharmaceuticals Stock Down 1.5 %

NYSEAMERICAN:ARMP opened at $1.95 on Thursday. Armata Pharmaceuticals has a one year low of $1.89 and a one year high of $4.48. The firm has a market capitalization of $70.55 million, a PE ratio of -1.19 and a beta of 0.78.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.